Know Labs (NYSE:KNW) announced today that it established a scientific advisory board to accelerate development for its glucose monitoring devices.
Seattle-based Know Labs expects the members to advise on algorithm refinement, device development, clinical trial design and research publication strategy. They’ll work alongside the company’s current medical and regulatory advisory board members.
The company develops its proprietary Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top form factors. Know Labs developed the first application of Bio-RFID as a non-invasive glucose monitor.
Get the full story at our sister site, Drug Delivery Business News.